Cargando…
PUS1 is a novel biomarker for predicting poor outcomes and triple-negative status in breast cancer
Breast cancer patients’ outcomes have improved dramatically in recent years, but relapses and poor prognosis remain common due to its aggressiveness and heterogeneity. The development of reliable biomarkers is still needed for predicting prognosis and treatment effectiveness. Recently, a growing bod...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705787/ https://www.ncbi.nlm.nih.gov/pubmed/36457503 http://dx.doi.org/10.3389/fonc.2022.1030571 |